Hemolytic Anemia

Data confirm the safety and efficacy of ravulizumab among patients with paroxysmal nocturnal hemoglobinuria previously treated with eculizumab, according to results of the REACTION study presented at ASH Annual Meeting and Exposition.

The FDA approved mitapivat for the treatment of hemolytic anemia in adults with pyruvate kinase deficiency.

Research presented at ASH Annual Meeting and Exposition provided an exciting update on many of the underappreciated clinical manifestations of cold agglutinin disease, as well as data on potential new therapeutic interventions.